UK Markets closed

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
213.70+4.30 (+2.05%)
At close: 05:29PM CEST

Swedish Orphan Biovitrum AB (publ)

Tomtebodavägen 23A
Solna 112 76
Sweden
46 86 97 20 00
https://www.sobi.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees1,554

Key executives

NameTitlePayExercisedYear born
Dr. Guido OelkersCEO & Pres23.4MN/A1965
Dr. Anders Ullman M.D., Ph.D.Head of R&D and Chief Medical Officer420kN/A1956
Mr. Henrik StenqvistChief Financial OfficerN/AN/A1968
Mr. Thomas Kudsk LarsenHead of Communication & Investor RelationsN/AN/A1974
Mr. Torbjörn HallbergGen. Counsel and Head of Legal Affairs & HRN/AN/A1969
Mr. Daniel RankinHead of Strategy & Corp. Devel.N/AN/A1980
Pablo de MoraHead of Global Marketing & AccessN/AN/A1968
Mr. Philip WoodHead of HaematologyN/AN/A1968
Ms. Konstantina KarampelaSr. Director of European Commercial Operations (Specialty Care and Partner Products)N/AN/AN/A
Mr. Armin Reininger M.D., Ph.D.Head of Medical & Scientific AffairsN/AN/A1957
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Corporate governance

Swedish Orphan Biovitrum AB (publ)’s ISS governance QualityScore as of 31 July 2022 is 2. The pillar scores are Audit: 5; Board: 2; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.